Patient Engagement at a Tipping Point-The Need for Cultural Change Across Patient, Sponsor, and Regulator Stakeholders: Insights From the DIA Conference, "Patient Engagement in Benefit Risk Assessment Throughout the Life Cycle of Medical Products".

Smith, Meredith Y; Hammad, Tarek A; Metcalf, Marilyn; Levitan, Bennett; Noel, Rebecca; Wolka, Anne M; Michaels, Debra L; Johnson, F Reed

Smith, Meredith Y; Hammad, Tarek A; Metcalf, Marilyn; Levitan, Bennett; Noel, Rebecca; Wolka, Anne M; Michaels, Debra L; Johnson, F Reed.

Afiliação

Smith MY; 1 Amgen, Thousand Oaks, CA, USA.
Hammad TA; 2 Merck & Company Inc, Kenilworth, NJ, USA.
Metcalf M; 3 GlaxoSmithKline, Research Triangle Park, NC, USA.
Levitan B; 4 Janssen Research & Development, Titusville, NJ, USA.
Noel R; 5 Eli Lilly and Company, Indianapolis, IN, USA.
Wolka AM; 5 Eli Lilly and Company, Indianapolis, IN, USA.
Michaels DL; 6 DIA, Horsham, PA, USA.
Johnson FR; 7 Duke Clinical Research Institute, Durham, NC, USA.

Ther Innov Regul Sci ; 50(5): 546-553, 2016 Sep.

Article em En | MEDLINE | ID: mdl-30231755

Palavras-chave

benefit-risk; drug development; medical decision making; patient engagement; patient outcomes; patient perspective

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Guideline / Risk_factors_studies Idioma: En Revista: Ther Innov Regul Sci Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google